BRPI0516488A - azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1 - Google Patents

azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1

Info

Publication number
BRPI0516488A
BRPI0516488A BRPI0516488-5A BRPI0516488A BRPI0516488A BR PI0516488 A BRPI0516488 A BR PI0516488A BR PI0516488 A BRPI0516488 A BR PI0516488A BR PI0516488 A BRPI0516488 A BR PI0516488A
Authority
BR
Brazil
Prior art keywords
azolidinones
antiproliferative activity
naphthyridine
cdk1
cdk1 antiproliferative
Prior art date
Application number
BRPI0516488-5A
Other languages
English (en)
Inventor
Jin-Jun Liu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0516488A publication Critical patent/BRPI0516488A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

AZOLIDINONAS DE 1,5-NAFTIRIDINA TENDO ATIVIDADE ANTIPROLIFERATIVA DE CDK1. A presente invenção refere-se a azolidinonas de 1 ,5-Naftiridina da fórmula I para processos para fabricação dos referidos compostos, bem como medicamentos contendo-os. Estes compostos são inibidores de CDK1 e mostram atividade antiproliferativa. Eles são portanto úteis como agentes anti-câncer.
BRPI0516488-5A 2004-10-14 2005-10-05 azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1 BRPI0516488A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61880704P 2004-10-14 2004-10-14
PCT/EP2005/010716 WO2006040052A1 (en) 2004-10-14 2005-10-05 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity

Publications (1)

Publication Number Publication Date
BRPI0516488A true BRPI0516488A (pt) 2008-09-09

Family

ID=36013291

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516488-5A BRPI0516488A (pt) 2004-10-14 2005-10-05 azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1

Country Status (11)

Country Link
US (1) US7268231B2 (pt)
EP (1) EP1805174A1 (pt)
JP (1) JP2008516905A (pt)
KR (2) KR100875408B1 (pt)
CN (1) CN101039944B (pt)
AU (1) AU2005293835A1 (pt)
BR (1) BRPI0516488A (pt)
CA (1) CA2583192A1 (pt)
MX (1) MX2007004276A (pt)
RU (1) RU2405781C2 (pt)
WO (1) WO2006040052A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
TW200745066A (en) 2005-09-16 2007-12-16 Torrent Pharmaceuticals Ltd Novel PTP1B inhibitors
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
CN101555248B (zh) * 2009-05-22 2011-06-22 北京欧凯纳斯科技有限公司 一种多取代1,5-萘啶化合物的制备方法
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) * 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
RU2521390C1 (ru) * 2013-03-14 2014-06-27 Общество с ограниченной ответственностью "Тиацен" Производное роданина и средство для профилактики опухолевых заболеваний
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
WO2015144804A1 (en) 2014-03-26 2015-10-01 Astex Therapeutics Ltd Combinations
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
TWI834020B (zh) 2015-02-10 2024-03-01 英商阿斯迪克治療公司 新穎組成物
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
WO2017050865A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
WO2017050864A1 (en) 2015-09-23 2017-03-30 Janssen Pharmaceutica Nv New compounds
JP2022524103A (ja) 2019-03-08 2022-04-27 メビオン・メディカル・システムズ・インコーポレーテッド カラム別の放射線の照射およびそのための治療計画の生成
KR20230005197A (ko) 2020-04-30 2023-01-09 페르하 파마슈티컬스 특정 dyrk1a, clk1 및/또는 clk4에서 단백질 키나제의 억제제로서의 신규한 이미다졸론 유도체
EP3904354A1 (en) * 2020-04-30 2021-11-03 Perha Pharmaceuticals New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
AR124154A1 (es) 2020-11-27 2023-02-22 Rhizen Pharmaceuticals Ag Inhibidores de cdk
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
EP4173674A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2151770C1 (ru) * 1994-06-14 2000-06-27 Дайниппон Фармасьютикал Ко., Лтд. Производные пиридонкарбоновой кислоты, способы их получения, противоопухолевое средство и фармацевтическая композиция
MXPA05000453A (es) * 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
CA2507256A1 (en) * 2002-11-22 2004-06-10 Smithkline Beecham Corporation Thiazolidine compounds in the treatment of anemic conditions

Also Published As

Publication number Publication date
RU2405781C2 (ru) 2010-12-10
JP2008516905A (ja) 2008-05-22
CN101039944B (zh) 2010-05-05
KR20080075235A (ko) 2008-08-14
EP1805174A1 (en) 2007-07-11
RU2007117765A (ru) 2008-11-20
CN101039944A (zh) 2007-09-19
WO2006040052A1 (en) 2006-04-20
US7268231B2 (en) 2007-09-11
KR100875408B1 (ko) 2008-12-23
CA2583192A1 (en) 2006-04-20
MX2007004276A (es) 2007-05-16
US20060084673A1 (en) 2006-04-20
AU2005293835A1 (en) 2006-04-20
KR20070053332A (ko) 2007-05-23

Similar Documents

Publication Publication Date Title
BRPI0516488A (pt) azolidinonas de 1,5-naftiridina tendo atividade antiproliferativa de cdk1
UY29633A1 (es) Derivados de oxindol
UY27891A1 (es) Nuevos derivados de glicosido de tiofeno, procedimientos para la preparación de los mismos, medicamentos que contienen estos compuestos, y el uso de los mismos.
UY29300A1 (es) Compuestos quimicos
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
BRPI0514665A2 (pt) compostos com atividade antibacteriana, composições farmacêuticas e uso dos mesmos
SE0302811D0 (sv) Novel compounds
TW200615266A (en) Organic compounds
ECSP055899A (es) Pirimidinas inhibidoras de chk, pdk y akt, su producción y su uso como agentes farmacéuticos
UY28990A1 (es) Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso.
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
BRPI0514731A (pt) derivados de pirimidina
CR9469A (es) Derivados de urea, metodos para su fabricacion y usos para los mismos
ATE556074T1 (de) Neue imidazoä1,5-aüpyridinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
GT200300033A (es) Derivados de nicotinamida utiles como inhibidores de pde4
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
DE502005008057D1 (de) Substituierte cyclopenten-verbindungen
SE0403086D0 (sv) Compounds
BRPI0511390A (pt) tiazolinona quinolinas não-substituìdas
BRPI0512843A (pt) inibidores de quinolina
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2212 DE 28/05/2013.